Novopulmon Novolizer (Budesonide)

Budesonide, the active ingredient in Novopulmon Novolizer, is a glucocorticoid presented as a corticosteroid anti‑inflammatory for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) in adults and adolescents. GNH USA supplies Novopulmon Novolizer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Novopulmon Novolizer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Novopulmon Novolizer delivers budesonide directly to the airways, addressing inflammatory airway diseases.

- Asthma: improves lung function and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): decreases airway inflammation and helps maintain airflow. - Allergic rhinitis: alleviates nasal congestion and inflammatory symptoms when used as part of a combined therapy regimen.

Adverse reactions may occur with inhaled budesonide, ranging from mild to serious.

Common Side Effects: - Oral candidiasis: fungal infection of the mouth. - Hoarseness: voice changes after inhalation. - Throat irritation: mild discomfort in the throat. - Cough: transient coughing after use. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening of breathing difficulty. - Adrenal suppression: reduced cortisol production with high‑dose or prolonged use. - Pneumonia: especially in patients with COPD. - Severe hypersensitivity: anaphylaxis or angioedema. - Osteoporosis: decreased bone mineral density with long‑term high‑dose therapy.

When using Novopulmon Novolizer, consider the following safety measures:

- Monitor lung function: regular assessment of respiratory status. - Educate on technique: ensure correct inhaler use to minimise oral deposition. - Review concomitant meds: assess for potential drug interactions. - Assess infection risk: watch for signs of respiratory infections. - Evaluate bone health: consider calcium and vitamin D supplementation for long‑term users. - Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Budesonide may interact with several drug classes; clinicians should evaluate the relevance of each interaction.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure. - Systemic immunosuppressants: additive immunosuppression risk.

Moderate Interactions (Monitor Closely): - Antifungal azoles: may modestly raise budesonide levels. - Ritonavir: potential increase in systemic corticosteroid effects. - Live vaccines: reduced vaccine efficacy due to immunosuppression. - Diuretics: may enhance fluid retention when systemic exposure is high. - Oral hypoglycaemic agents: possible alteration of glucose control.